Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001600620-24-000118
Filing Date
2024-11-25
Accepted
2024-11-25 16:28:21
Documents
1
Period of Report
2024-11-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1732570094.html 4  
1 FORM 4 wk-form4_1732570094.xml 4 5357
  Complete submission text file 0001600620-24-000118.txt   6743
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Issuer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address #1203-4464 MARKHAM STREET VICTORIA A1 BC V8Z7X8
Business Address
Jayne David R.W. (Reporting) CIK: 0001838242 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36421 | Film No.: 241496294